Clinical Trials Directory

Trials / Unknown

UnknownNCT04262934

Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in hemoDIALysis Patients?

Multicenter Randomized Study : Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in hemoDIALysis Patients?

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Institut Phoceen de Nephrologie · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Muscle strength decreases as renal failure progresses. Low muscle strength affects more than 50% of hemodialysis patients and leads to daily life activities impairment. In the general population, numerous studies have linked low 25OH-vitamin D (25OHD) concentrations to the loss of the muscle strength and low physical performances. Data on native vitamin D and muscle function are scarce in the chronic renal failure (CKD) population, but low 25OHD levels have been associated with poor muscle strength. In this protocol of an ongoing study named VITADIAL testing if cholecalciferol supplementation in hemodialysis patients with low 25OHD improve their muscle strength.

Detailed description

Prospective open randomized French multicenter study. All patients will have 25OHD levels ≤50nmol/L at randomization. One group will receive 100 000 UI cholecalciferol once a month during 6 months, the other group will receive no treatment during 6 months. In order to randomize patients with 25OHD ≤50nmol/L, supplemented patients will undergo a 3 months wash-out period renewable 3 times (maximum of 12 months wash-out) until 25OHD reaches a level≤50nmol/L. The main objective of this study is to analyze if a 6 months period of oral cholecalciferol (i.e. native vitamin D) supplementation improves muscle strength of hemodialysis patients with low 25OHD vitamin D levels. Muscle strength will be assessed at 0, 3 and 6 months, by handgrip strength measured with a quantitative dynamometer. Secondary objectives are 1) to analyze 25OHD plasma levels after vitamin D wash-out and/or supplementation, as well as factors associated with 25OHD lowering speed during wash-out and 2) to analyze if this supplementation improves patient's autonomy, reduces frailty risk and improves quality of life.

Conditions

Interventions

TypeNameDescription
DRUGCholecalciferol 100.000 UI administrationOne oral Administration - Every month
OTHERNo vitamin D administrationNo vitamin D administration

Timeline

Start date
2018-01-08
Primary completion
2024-06-08
Completion
2024-06-08
First posted
2020-02-10
Last updated
2022-08-11

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04262934. Inclusion in this directory is not an endorsement.